Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984773 | 1.00 | CTSK (0.54) | CTSKCTSBCTSSSLC6A2SLC6A4 | |
| SCHEMBL4988314 | 0.86 | CTSK (0.67) | CTSKCTSBCTSL | |
| SCHEMBL4986475 | 0.85 | CTSK (0.52) | CTSKCTSBCTSSCTSL | |
| SCHEMBL4989195 | 0.81 | CTSB (0.54) | CTSKCTSBCTSSCTSL | |
| SCHEMBL1375968 | 0.80 | CTSK (0.59) | CTSKCTSBCTSSCTSL | |
| SCHEMBL4987675 | 0.80 | CTSK (0.56) | CTSKCTSBCTSSSLC6A2SLC6A4 | |
| SCHEMBL4986668 | 0.79 | CTSK (0.65) | CTSKCTSBCTSSCTSL | |
| SCHEMBL1376012 | 0.79 | CTSK (0.62) | CTSKCTSBCTSSCTSL | |
| SCHEMBL4986641 | 0.78 | CTSK (0.65) | CTSKCTSBCTSSCTSL | |
| SCHEMBL1379348 | 0.78 | CTSK (0.65) | CTSKCTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644326-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000800-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-01-06 | — | — | WO | disclosed |